Postlicensure study of varicella vaccine effectiveness in a day-care setting

Pediatric Infectious Disease Journal

Volumn 18, Issue 12, 1999, Pages 1047-1050

  Clements, Dennis A ^a   Moreira, Sandra P ^a   Coplan, Paul M ^b   Bland, Christine L ^a   Walter, Emmanuel B ^a  

^a DUKE CHILDREN S HOSPITAL   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Day care; Oka Merck; Varicella vaccine

Indexed keywords

CHICKENPOX VACCINE;

ARTICLE; CALCULATION; CHEMOPROPHYLAXIS; CHICKENPOX; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DAY CARE; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; HUMAN EXPERIMENT; INFANT; MATHEMATICAL ANALYSIS; NORMAL HUMAN; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL;

EID: 0032761564     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199912000-00004     Document Type: Article

References (22)

1. White CJ. Clinical trials of varicella vaccine in healthy children. Infect Dis Clin North Am 1996;10:595-608.
2. Kuter BJ, Weibel RE, Guess HA, et al. Varicella (Oka/Merck) vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies. Vaccine 1991;9:643-7.
3. Johnson C, Rome LP, Stancin T, Kumar ML. Humoral immunity and clinical reinfections following varicella vaccine in healthy children. Pediatrics 1989;84:418-421.
4. Osaki T, Matsui T, Ichikawa R, et al. Clinical trial of the Oka strain of live attenuated varicella vaccine on healthy children. Biken J 1984;27:39-42.
5. Watson BM, Piercy SA, Plotkin SA, Starr SE. Modified chickenpox in children immunized with the Oka/Merck varicella vaccine. Pediatrics 1993;91:17-22.
6. Weibel RE, Kuter BJ, Neff BJ et al. Live Oka/Merck varicella vaccine in healthy children. JAMA 1985;254:2435-9.
7. Andre FE. Worldwide experience with Oka strain live varicella vaccine. Postgrad Med J 1985;61(Suppl 4):113-20.
8. Asano Y, Nagai T, Miyata R, et al. Long-term protective immunity of recipients of the Oka strain of varicella virus vaccine. Pediatrics 1985;75:667-71.
9. White CJ, Kuter BJ, Ngai A, et al. Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response. Pediatr Infect Dis J 1992;11:19-23.
10. Bernstein HH, Rothstein EP, Penridge Pediatric Associates, et al. Clincial survey of natural varicella compared with breakthrough varicella after immunization with live attenuated varicella (Oka/Merck) vaccine. Pediatrics 1993;92: 833-7.
11. Clements DA. Modified varicella-like syndrome. Infect Dis Clin North Am 1996;10:617-29.
12. Hall C, Chesney PJ, Gromisch D, et al. Recommendations for the use of the live attenuated varicella vaccine: American Academy of Pediatrics. Pediatrics 1995;95:791-6.
13. Merck Varivax package insert.
14. Izurieta HS, Strebel PM, Blake PA. Postlicensure effectiveness of varicella vaccine during an outbreak in a child care center. JAMA 1997;278:1495-9.
15. Orenstein WA, Bernier RH, Hinman AR. Assessing vaccine efficacy in the field. Epidemiol Rev 1988;10:221-41.
16. Dean AG, Dean JA, Coulombier D, et al. Epi-Info, Version 6.03: a word processing, database, and statistics program for public health on IBM compatible microcomputers. Atlanta, GA: Centers for Disease Control and Prevention, 1995.
17. Clements DA, Armstrong CB, Ursano AM, Moggio MV, Walter EB, Wilfert CM. Over five-year follow-up of Oka/ Merck varicella vaccine recipients in 465 infants and adolescents. Pediatr Infect Dis J 1995;14:874-9.
18. Dagan R, Fraser D, Greif Z, et al. A nationwide prospective surveillance study in Israel to document pediatric invasive infections, with an emphasis on Haemophilus influenzae type b infections. Pediatr Infect Dis J 1998;17:S198-203.
19. Harrison LH, Tajkowski C, Croll J, et al. Postlicensure effectiveness of the Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer-membrane protein complex conjugate vaccine among Navajo children. J Pediatr 1994;125:571-6.
20. Peltola H, Aavitsland P, Hansen KG, Jonsdottir KE, Nokleby H, Romanus V. Perspective: a five-country analysis of the impact of four different Haemophilus influenzae type b conjugates and vaccination strategies in Scandinavia. J Infect Dis 1999;179:223-9.
21. Miller E, Gay NJ. Epidemiological determinants of pertussis. Dev Biol Stand 1997;89:15-23.
22. Flugsrud LB, Rld TO, Aasen S, Berdal BP. Measles antibodies and herd immunity in 20-and 40-year-old Norwegians. Scand J Infect Dis 1997;29:137-40.